Pulse Biosciences Inc
NASDAQ:PLSE
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
US |
Pulse Biosciences Inc
NASDAQ:PLSE
|
416.9m USD | -8.6 | ||
US |
Abbott Laboratories
NYSE:ABT
|
182.6B USD | 28.6 | ||
US |
Intuitive Surgical Inc
NASDAQ:ISRG
|
141.7B USD | 73.4 | ||
US |
Stryker Corp
NYSE:SYK
|
127.3B USD | 30.2 | ||
IE |
Medtronic PLC
NYSE:MDT
|
113.2B USD | 20.2 | ||
US |
Boston Scientific Corp
NYSE:BSX
|
109.7B USD | 46.2 | ||
US |
Becton Dickinson and Co
NYSE:BDX
|
68.4B USD | 39.7 | ||
DE |
Siemens Healthineers AG
XETRA:SHL
|
60.6B EUR | 32.1 | ||
US |
Edwards Lifesciences Corp
NYSE:EW
|
54.4B USD | 30.3 | ||
CN |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
378.2B CNY | 28.6 | ||
US |
Dexcom Inc
NASDAQ:DXCM
|
51.7B USD | 78.8 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.